Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Arana Therapeutics has successfully completed a collaborative project with its pharmaceutical partner CSL Limited, triggering a further payment to Arana from CSL under the terms of the collaboration agreement between the two companies.
Subscribe to our email newsletter
Under the agreement, signed in June 2006 and extended to cover additional work in December 2006, Arana utilized its superhumanization technology to develop humanized versions of lead antibodies from the CSL pharmaceutical pipeline. These humanized products have then been affinity matured using Arana’s EvoGene optimization technology.
If CSL chooses to develop one of these antibodies through clinical testing, Arana will be eligible to receive milestone payments and will earn royalty payments on the sale of all marketed products.
John Chiplin, CEO of Arana, said: “The completion of the project with CSL continues to deliver on the success of the technology partnerships that the company has very successfully built upon over the last two years.”